Brandon C. Rosen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brandon C. Rosen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Barber-Axthelm
Oregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA
1 shared publication - Aaron Yrizarry-Medina
Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA
1 shared publication - Benjamin J. Burwitz
Oregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA
1 shared publication - Benjamin N. Bimber
Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, USA
1 shared publication - Caralyn S. Labriola
Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, USA
1 shared publication - Christakis Panayiotou
George Washington University, Washington DC, USA
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (16)
Prophylactic and therapeutic neutralizing monoclonal antibody treatment prevents lethal yellow fever infection
Yellow fever virus (YFV) infection is fatal in 5%–10% of the 200,000 yearly cases. There is currently no available antiviral treatment. We showed previously that administration of 50 mg/kg of a YFV-specific neutralizing monoclonal antibody (nmAb) at 2 days postinfection (dpi), prior to the onset of severe disease, protected YFV-infected rhesus macaques from death. To further explore the clinical applicability of our nmAb MBL-YFV-01, we treated rhesus macaques with a lower dose (10 mg/kg) of this nmAb prophylactically or therapeutically at 3.5 dpi. We show that a single prophylactic or therapeutic i.v. dose of our nmAb protects rhesus macaques from death following challenge. A comprehensive analysis of 167 inflammatory cytokine and chemokines revealed that protection was associated with significantly reduced expression of 125 of these markers, including type I IFN, IL-6, and CCL2. This study further expands the potential clinical use of our YFV-specific nmAb, which could be used during an outbreak for immediate prophylactic immunity or for patients with measurable serum viremia.
- 15 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (16)
Open AccessProphylactic and therapeutic neutralizing monoclonal antibody treatment prevents lethal yellow fever infection
Yellow fever virus (YFV) infection is fatal in 5%–10% of the 200,000 yearly cases. There is currently no available antiviral treatment. We showed previously that administration of 50 mg/kg of a YFV-specific neutralizing monoclonal antibody (nmAb) at 2 days postinfection (dpi), prior to the onset of severe disease, protected YFV-infected rhesus macaques from death. To further explore the clinical applicability of our nmAb MBL-YFV-01, we treated rhesus macaques with a lower dose (10 mg/kg) of this nmAb prophylactically or therapeutically at 3.5 dpi. We show that a single prophylactic or therapeutic i.v. dose of our nmAb protects rhesus macaques from death following challenge. A comprehensive analysis of 167 inflammatory cytokine and chemokines revealed that protection was associated with significantly reduced expression of 125 of these markers, including type I IFN, IL-6, and CCL2. This study further expands the potential clinical use of our YFV-specific nmAb, which could be used during an outbreak for immediate prophylactic immunity or for patients with measurable serum viremia.